Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention

International Journal of Cardiology

Volumn 107, Issue 2, 2006, Pages 241-246

  Danzi, Gian B ^a   Sesana, Marco ^a   Capuano, Cinzia ^a   Mauri, Luigi ^a   Predolini, Simonetta ^a   Baglini, Roberto ^a  

^a Casa di Cura Poliambulanza   (Italy)

Author keywords

Angina; Angioplasty; Glycoproteins; Platelets

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; TICLOPIDINE; TIROFIBAN;

ADULT; AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; GENDER; HIGH RISK PATIENT; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); CORONARY ANGIOGRAPHY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 30444441422     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.03.025     Document Type: Article

References (20)

1. E. Braunwald, E.M. Antman, J.W. Beasley, R.M. Califf, M.D. Cheitlin, and J.S. Hochman ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) J Am Coll Cardiol 40 2002 1366 1374
2. C.W. Hamm, M. Bertrand, and E. Braunwald Acute coronary syndrome without ST elevation: implementation of new guidelines Lancet 358 2001 1533 1538
3. D.P. Chew, M. Roffi, and E.J. Topol Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes Prog Cardiovasc Dis 44 2001 195 206
4. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction N Engl J Med 338 1998 1488 1497
5. C.P. Cannon, W.S. Weintraub, L.A. Demopoulos, R. Vicari, M.J. Frey, and N. Lakkis Comparison of early invasive and conservative strategies in patients with unstable coronary syndrome treated with the glycoprotein IIb/IIIa inhibitor tirofiban N Engl J Med 344 25 2001 1879 1887
6. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
7. E.J. Topol, D.J. Moliterno, H.C. Herrmann, E.R. Powers, C.L. Grines, and D.J. Cohen Comparison of two glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 344 2001 1888 1894
8. S.S. Kabbani, A. Aggarwal, E.F. Terrien, P.M. DiBattiste, B.E. Sobel, and D.J. Schneider Suboptimal early inhibition of platelets by treatment with tirofiban and implication for coronary interventions Am J Cardiol 89 2002 647 650
9. H.C. Herrmann, T.A. Swierkosz, S. Kapoor, D.C. Tardiff, P.M. DiBattiste, and J.W. Hirshfeld Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention Am J Cardiol 89 2002 1293 1297
10. D.J. Schneider, H.C. Herrmann, N. Lakkis, F. Aguirre, Y. Wan, and A. Aggarwal Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban Am J Cardiol 90 2002 1421 1423
11. D.J. Schneider, H.C. Herrmann, N. Lakkis, F. Aguirre, M.W. Lo, and K.C. Yin Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus dose of tirofiban Am J Cardiol 91 2003 334 336
12. TIMI Study Group The thrombolysis in myocardial infarction (TIMI) trial: phase 1 findings N Engl J Med 312 1985 932 936
13. G. Tommasini, P. Rubartelli, and M. Piaggio A deterministic approach to automated stenosis quantification Catheter Cardiovasc Interv 48 1999 435 445
14. T.J. Ryan, D.P. Faxon, R.M. Gunnar, J.W. Kennedy, S.B. King III, and F.D. Loop Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures Circulation 78 1988 486 502
15. F.J. Neumann, A. Kastrati, G. Pogatsa-Murray, J. Mehilli, H. Bollwein, and H.P. Bestehorn Evaluation of prolonged antithrombotic pretreatment (cooling-off strategy) before intervention in patients with unstable coronary syndromes. A randomized controlled trial JAMA 290 2003 1593 1599
16. D.J. Kereiakes, M. McDonald, T. Broderick, E.M. Roth, D.D. Whang, and L.H. Martin Platelet glycoprotein IIb/IIIa receptor blockers: an appropriate-use model for expediting care in acute coronary syndromes Am Heart J 139 2000 S53 S60
17. G.B. Danzi, C. Capuano, M. Sesana, and R. Baglini Safety of high bolus dose of tirofiban during stent placement Catheter Cardiovasc Interv 61 2004 179 184
18. G.B. Danzi, M. Sesana, C. Capuano, L. Mauri, P. Berra Centurini, and R. Baglini Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function Am J Cardiol 94 2004 35 39
19. M. Valgimigli, G. Precoco, D. Barbieri, F. Ferrari, G. Guardigli, and G. Parrinello The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty. The ADVANCE trial J Am Coll Cardiol 44 2004 14 19
20. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularisation N Engl J Med 336 1997 1689 1696